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INTRODUCTION: 
Chronomodulated delivery systems have attracted 
because of their multiple benefits over conventional 
dosage forms. These systems deliver the drug at the 
right time, at the right site of action and in the right 
amount, which provides increased patient compliance 
and more benefits compared to conventional dosage 
forms. These systems are designed to release the drug 
after a predetermined lag time that matches the 
chronobiological requirements of the given disease 
condition. Thus, these systems are beneficial for drugs 
which are used in the treatment of certain diseases like 
asthma, rheumatoid arthritis and various 
cardiovascular conditions that exhibit circadian 
rhythmicity. Chronomodulated delivery systems are 
also useful where nocturnal dosing is required, and for 
drugs that show the first-pass effect
1,2
. 
Compared to single-unit dosage forms, multiparticlate 
systems like microspheres exhibit more uniform 
distribution and absorption of the drug in the 
gastrointestinal tract, reduced local irritation, higher 
colonic residence time, more predictable gastric 
emptying and also eliminates unwanted intestinal 
retention of polymeric material
3,4
. Carboxymethyl 
chitosan, a water soluble derivative of chitosan, with 
enhanced biological and physicochemical properties 
compared to chitosan, has emerged as a promising 
candidate for different biomedical applications. The 
biodegradability and biocompatibility of 
ABSTRACT: 
The present study deals with the design and evaluation of chronomodulated delivery of terbutaline sulphate as a 
chronotherapeutic approach in the treatment of nocturnal asthma. The basic design is based on the Pulsincap technology and 
consisted of formaldehyde treated insoluble hard gelatin capsule body filled with glutaraldehyde cross-linked carboxymethyl 
chitosan microspheres of terbutaline sulphate and sealed with a hydrogel tablet plug. The entire device was enteric coated, so 
as to prevent the variable gastric emptying time. The glutaraldehyde cross-linked carboxymethyl chitosan microspheres 
appeared to be roughly spherical with the size range of 4.63±0.48 to 11.75±0.92µm. The prepared microspheres possessed 
good yield and high encapsulation efficiency. Particle size, encapsulation efficiency and release rate are dependent on the 
fabrication conditions of the microspheres. Drug release from the microspheres depended on the core: coat ratio, reaction time 
and the rotational speed used in the preparation of microspheres.  Formaldehyde treatment efficiently rendered the hard 
gelatine capsule bodies water insoluble. The ejection of the plug from the chrnomodulated delivery system depended on the 
nature and concentration of polymer used in the preparation of table plug. A lag time of 3-8hrs was observed for the 
chronomodulated delivery systems prepared with different hydrogel plugging materials. Among the different polymers 
studied, HPC showed highest lag time compared to HPMC K4 M and sodium alginate. The Roentgenographic studies 
revealed the predicted in vivo performance of the developed chronomodulated delivery systems of terbutaline sulphate. 
Pharmacokinetic analysis revealed the significant increase in tmax, AUC and MRT of optimized chronomodulated system of 
terbutaline sulphate compared to that of pure drug. The results of the study conclusively proved the suitability of 
carboxymethyl chitosan microspheres and the adopted Pulsincap technology in the development of chronomodulated delivery 
systems for terbutaline sulphate in the treatment of nocturnal asthma.    
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carboxymethyl chitosan along with its permeation 
enhancing property makes it an ideal polymer for the 
development of drug delivery systems
5,6
. 
Asthma is a disease characterized by chronic 
inflammation of the airways and linked with airway 
hyper-responsiveness resulting in episodes of 
wheezing, shortness of breath, chest tightness, and 
cough, particularly at night or in the early morning. 
The worsening of asthma particularly at night is 
commonly referred to as nocturnal asthma (NA). 
Nocturnal asthma is a variable exacerbation of the 
underlying asthma condition associated with increases 
in symptoms, need for medication, airway 
responsiveness, and/or worsening of lung function. 
Approximately two-thirds of total asthmatics suffer 
from night time symptoms. Lung function (e.g., peak 
expiratory flow rate or FEV1) is usually highest at 4 
PM and lowest at 4 AM
7
. 
Terbutaline sulphate is a potent β-adrenoreceptor 
agonist widely used in the treatment of asthma
8,9
. The 
absorption of terbutaline sulphate form the 
gastrointestinal tract is variable and only 33-50% of 
the total administered oral dose is believed to be 
absorbed of which 60% is metabolized by the liver 
under the first pass effect
10
. The drug also undergoes 
gut wall metabolism
11
. Due to these factors the oral 
bioavailability of the drug is only 15% of the total 
administered dose
12
. Further the drug is also having 
short half life of 3-4hrs requiring frequent 
administration
13
. Thus, development and evaluation of 
chronomodulated delivery systems of terbutaline 
sulphate has been undertaken since the advantages of 
such systems also includes the better utilization of 
drugs having short half life with extensive first pass 
metabolism thereby providing better therapeutic 
outcome for nocturnal asthma. 
MATERIALS AND METHODS: 
Terbutaline sulphate pure drug was generously 
supplied by Shimoga Chemicals, Sangli, Maharashtra. 
Carboxymethyl chitosan was obtained as gift sample 
from Pelican Biotech Pvt Ltd, Kuthiathode, Kerala. 
Sodium Alginate and HPMC K4M were purchased 
from Himedia Lab Pvt Ltd, MumbaiandS.D Fine 
Chemicals, Mumbai respectively. Hard gelatine 
capsules were generously supplied by Elegant Drugs 
Pvt Ltd, Hubli, Karnataka. All other chemicals and 
reagents were of analytical grade and were purchased 
from SD fine chemicals, Mumbai. 
Preparation of microspheres 
Carboxymethyl chitosan microspheres loaded with 
terbutaline sulphate were prepared by emulsion cross 
linking technique. Accurately weighed quantity of 
carboxymethyl chitosan (3%w/v) was dissolved in 
distilled water by stirring on a magnetic stirrer. 
Thereafter, known quantity of terbutaline sulphate was 
added to the above polymeric solution. The resulting 
solution was added drop wise into 40 ml of light and 
heavy liquid paraffin (1:1) containing 1% w/w of span-
8o (needle no: 22G) at 1000 rpm using digital 
overhead stirrer. The system was allowed for 
emulsification for 30 minutes and then 2 ml of 
glutaraldehyde (25% v/v aqueous solution) was added 
and stirring was continued for the specified time 
period. Microspheres thus obtained were filtered and 
washed several times with petroleum ether to remove 
traces of oil and then they were finally washed with 
ethanol to remove excess amount of glutaraldehyde. 
The microspheres were then dried at room temperature 
for 24 hrs
14,15
. The formulation details of terbutaline 
sulphate loaded carboxymethyl chitosan is given in 
Table No: 1 
Characterization of microspheres 
Particle size and surface topography 
The size of the prepared microspheres was analyzed 
using optical microscopy fitted with a calibrated eye 
piece micrometer. The mean of 100 microspheres was 
noted as average particle size
16
. The surface 
topography of the microspheres was studied using 
scanning electron microscopy (JEOL, JSM-6360, 
Japan). Microspheres were mounted on aluminium 
specimen studs using double sided adhesive tape and 
coated with platinum under vacuum. The morphology 
of the microspheres was observed at acceleration 
voltage of 10 kV at different magnifications. The 
results of the particle size analysis and surface 
topography is given Table No 1 and Fig No 1 
respectively. 
Percentage Yield 
The percentage yield (PY) was calculated based on the 
dry weight of drug and the polymer used in the 
preparation of microspheres and total quantity of 
product obtained. The following equation was used in 
the calculation of percentage of yield
17
: 
               
 
                           
                                          
     
Encapsulation efficiency 
Crushed microspheres equivalent to 5 mg of 
terbutaline sulphate was accurately weighed and 
transferred to a 100ml volumetric flask containing 
50ml of phosphate buffer of pH 7.4 and the volume 
was made up to the mark using the same buffer 
solution. The flask was stirred on a thermostatic water 
bath at room temperature for 24 h to extract the 
entrapped drug. The content was filtered and after 
suitable dilution, the absorbance was noted on a UV 
spectrophotometer at 281.0 nm using phosphate buffer 
of pH 7.4 as blank. Triplicate readings for each batch 
were noted and the average was determined as drug 
content of the microspheres
18
. 
The encapsulation efficiency was calculated using the 
below formula: 
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Table 1: Formulation and Characterization of terbutaline sulphate loaded carboxymethyl chitosan 
microspheres 
 
Code 
Variables Physicochemical characterization 
Core: coat  Yield (%) Actual Drug 
content(mg)* 
Encapsulation 
Efficiency (%) 
Particle Size 
(µm) 
C1 1:2 constant: 
1000 rpm 
1% span 
6 hrs 
85.05±1.67 3.90±0.15 78.13±3.98 5.03±0.57 
C2 1:4 88.95±1.42 4.06±0.25 81.33±5.07 6.38±0.35 
C3 1:6 91.15±1.20 4.31±0.17 86.26±3.52 9.04±0.71 
C4 1:8 92.96±1.51 4.40±0.14 88.06±2.94 11.11±1.14 
 Reaction time     
R1 5hrs constant: 
1:6; 
1000 rpm; 
1% span 
89.28±0.93 4.14±0.15 82.93±3.0 10.13±1.10 
R2 7hrs 92.03±1.06 4.35±0.23 87.06±4.62 7.95±0.86 
R3 8hrs 93.07±1.67 4.46±0.17 89.2±3.53 6.57±0.61 
 Speed     
S1 1200 constant: 
1:6; 
1% span 
6hrs 
92.21±1.11 4.44±0.14 88.8±2.82 7.51±0.75 
S2 1400 89.16±1.49 4.38±0.18 87.73±3.75 6.87±0.38 
S3 1600 86.84±1.52 4.13±0.11 82.73±2.33 4.63±0.48 
 
In vitro drug release studies 
The release of terbutaline sulphate from the 
microspheres was studied using USP type II dissolution 
apparatus. Microspheres equivalent to 5 mg of 
terbutaline sulphate were taken into the basket and the 
release studies were carried out under the following 
conditions; media: 400 ml of phosphate buffer of pH 
6.8; temperature: 37 ±0.5 ˚C; speed: 100 rpm. At fixed 
interval of time, aliquots were withdrawn and replaced 
with fresh dissolution media to maintain the constant 
volume. The concentration of drug released at different 
time intervals was then determined by measuring the 
absorbance at 281.0 nm against blank using UV 
spectrophotometer.  
Kinetic modelling of drug release 
To investigate the drug release mechanism from the 
microspheres, the in-vitro release data was fitted into 
various kinetics models like zero order, first order, 
Higuchi’s equations. Further, the drug release 
mechanism was also analysed by Korsemeyer-Peppas 
equation. 
 
 
Table 2: Composition of different hydrogel tablet plug for the chronomodulated delivery systems of 
terbutaline sulphate. 
 
 
 
 
Sl 
No 
Batch 
code 
Sodium 
Alginate 
(mg) 
HPMC 
(mg) 
HPC 
(mg) 
Sodium 
CMC 
(mg) 
Spray Dried 
Mannitol 
(mg) 
Mg. 
Stearate 
(mg) 
Total 
weight 
(mg) 
1 SA1 60 --- --- --- 38 2 100 
2 SA2 50 --- --- --- 48 2 100 
3 SA3 40 --- --- --- 58 2 100 
4 SA4 30 --- --- --- 68 2 100 
5 HM1 --- 60 --- --- 38 2 100 
6 HM2 --- 50 --- --- 48 2 100 
7 HM3 --- 40 --- --- 58 2 100 
8 HM4 --- 30 --- --- 68 2 100 
9 HC1 --- --- 60 --- 38 2 100 
10 HC2 --- --- 50 --- 48 2 100 
11 HC3 --- --- 40 --- 58 2 100 
12 HC4 --- --- 30 --- 68 2 100 
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Table 3: Composition of chronomodulated drug delivery systems of terbutaline sulphate 
 
Code 
 
Weight of 
empty capsule 
(mg) 
Weight of 
microspheres* 
(mg) 
Weight of 
tablet Plug 
(mg) 
Total weight 
of  capsule 
(mg) 
Weight after 
enteric coating 
(mg) 
TSA1 60.73±0.42 39.41 100.69±0.62 200.83±0.69 216.92±2.41 
TSA2 60.76±0.40 39.41 100.36±0.46 200.53±0.61 218.35±2.06 
TSA3 61.14±0.55 39.41 99.96±0.48 200.51±0.80 217.83±2.36 
TSA4 60.91±0.53 39.41 100.54±0.39 200.86±0.78 220.37±2.09 
THM1 60.93±0.51 39.41 99.81±0.30 200.15±0.67 217.63±1.77 
THM2 61.1±0.44 39.41 100.54±0.59 201.05±0.52 219.37±1.23 
THM3 60.74±0.55 39.41 100.33±0.61 200.48±0.84 218.49±2.27 
THM4 60.81±0.51 39.41 100.74±0.57 200.96±0.58 221.09±2.15 
THC1 61.09±0.28 39.41 100.57±0.48 201.22±0.47 220.32±1.56 
THC2 60.88±0.34 39.41 99.98±0.62 200.27±0.84 218.83±1.77 
THC3 59.97±0.32 39.41 100.17±0.24 199.55±0.41 217.33±2.23 
THC4 60.86±0.41 39.41 100.92±0.66 201.19±0.92 220.51±2.11 
*Weight of microspheres equivalent to 5mg of terbutaline sulphate 
 
Development of chronomodulated drug delivery 
systems 
In the present investigation, Pulsincap
TM 
technology 
was used for the development of chronomodulated 
systems of terbutaline sulphate with some 
modifications
19-21
. Briefly, the hard gelatine capsule 
bodies were treated with formaldehyde vapours for 12 
hrs to render them water insoluble. The treated capsule 
bodies were filled with optimized microspheres 
containing 5 mg of terbutaline sulphate and sealed 
with a hydrogel tablet plug. The tablet plugs were 
prepared with various semisynthetic polymers like 
sodium alginate, HPMC K4M and HPC by direct 
compression technique using spray dried mannitol and 
magnesium stearate as diluent and flow promoter 
respectively. The joint of the microspheres loaded 
capsule bodies were sealed with a small amount of 5% 
ethyl cellulose ethanolic solution. The sealed capsules 
were enteric coated by dip coating method with 4% 
HPMCP 55 in 4:1 (v/v) mixture of 
dichloromethane:acetone, plasticized with 
dibutylphthalate (0.75%), to prevent variable gastric 
emptying. 
Evaluation of chronomodulated delivery systems:  
Formaldehyde treated gelatin capsule bodies 
The formaldehyde treated empty hard gelatin capsule 
bodies were evaluated for the presence of free 
formaldehyde
19
, physical changes like deformations, 
shrinkage, perforations and solubility.  
In vitro dissolution studies 
Dissolution studies were carried out by using USP 
XXIV dissolution apparatus (paddle method) to 
analyze the release of drug from the developed 
chronomodulated systems of terbutaline sulphate. 
Capsules were tied to paddle with a cotton thread so 
that the capsule should be immersed completely in 
dissolution media. In order to simulate the pH changes 
of the GI tract, sequential pH change method was 
adopted in the dissolution studies. Dissolution media 
of pH 1.2 was first used for 2 h (since the average 
gastric emptying time is 2 h), then removed and the 
fresh pH 7.4 phosphate buffer saline (PBS) was added. 
After 3 h (average small intestinal transit time is 3 h), 
the medium was removed and fresh phosphate buffer 
of pH 6.8 was added for subsequent hours. Four 
hundred milliliters of the dissolution medium was used 
at each time. Rotation speed was 100 rpm and 
temperature was maintained at 37±0.5 
o
C. Five 
milliliters of dissolution media was withdrawn at 
predetermined time intervals and fresh dissolution 
media was replaced.  The withdrawn samples were 
analyzed at 276.5 nm for acidic medium and at 281.0 
nm for phosphate buffer of pH 6.8 and 7.4 by UV 
absorption spectroscopy and the cumulative percentage 
release was calculated. The study was carried out in 
triplicate and the average readings were used to know 
the drug release.  
Kinetic modelling of drug release 
To investigate the drug release mechanism from the 
chronomodulated delivery systems, the in-vitro release 
data was fitted into various kinetics models like zero 
order, first order, Higuchi’s equations. Further, the 
drug release mechanism was also analysed by 
Korsemeyer-Peppas equation. 
In vivo Roentgenography studies: 
Roentgenography study, a comparatively safer 
technique was carried out in healthy male albino 
rabbits to assess the in vivo behaviour of the optimized 
chronomodulated delivery systems of terbutaline 
sulphate. The investigation was performed after 
obtaining approval from the institutional animal ethical 
committee (576/02/bc/CPCSEA,22/03/2002) of N.E.T 
Pharmacy College, Raichur, Karnataka. To closely 
mimic the human physiological environment of the 
gastro intestinal tract, rabbits were selected as animal 
model for evaluating the chronomodulated drug 
delivery systems. For this purpose, young and healthy 
male albino rabbits weighing 2.5 to 3.0 kg were 
selected (n=3). The animals were housed in individual 
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cages, and the experiments were conducted in a 
sanitized room at a temperature maintained at around 
24 °C. To render the chronomodulated delivery system 
visible in the X-ray images, the drug loaded 
microspheres were replaced with the barium sulphate 
loaded microspheres. The barium sulphate loaded 
microspheres were prepared using the same 
methodology as stated in the preparation of drug 
loaded microspheres. Rabbits were fasted overnight 
before the start of the study and the optimized 
chronomodulated delivery systems were administered 
with 10ml of water. The chronomodulated delivery 
system (capsule) was kept behind the tongue to avoid 
biting by rabbit. Free access to water was provided to 
the animals during the study period. At different time 
intervals (0, 2, 4, 6 and 8hrs) X-ray images were taken 
to follow the movement, location and the behaviour of 
the chronomodulated systems in different parts of 
gastro intestinal tract
22-24
. 
In vivo Pharmacokinetic studies: A reverse phase 
HPLC method with PDA detection was used for the 
estimation of terbutaline sulphate
25,26
. 
Instrumentation and chromatographic conditions: 
A Shimadzu Prominence HPLC system provided with 
DGU-20A3 degasser, LC-20AD binary pumps, SIL-
20AHT auto sampler, and SPD-M20A PDA detector 
was used. The chromatographic analysis was 
performed on Phenomenex C18- RP aqueous column 
(250 × 4.6mm, 5µ). Mobile phase consisting of 15mM 
ammonium acetate: methanol (70:30% v/v) was used 
in isocratic mode and the mobile phase was filtered 
through nylon disc filter of 0.45µm and sonicated for 3 
min before use. The flow rate was 1 mL/min and the 
injection volume was 20µL. PDA detection was 
performed at 230nm and the separation was achieved 
at ambient temperature. 
Construction of HPLC calibration curve: The stock 
solution of terbutaline sulphate 1mg/ml was prepared 
by dissolving 10 mg of drug in methanol and volume 
was adjusted to the mark with the same solvent in a 
100ml volumetric flask. Calibration standards were 
prepared in rabbit plasma by adding appropriate 
volumes from the stock solution to drug free blank 
plasma and then serially diluting it with blank plasma 
to attain the concentration range of 5-500ng/ml.   
Plasma Extraction: 
The 200 µL aliquot of each samples were taken into 
polypropylene tube, 10 µL of 100 µg/mL IS  was 
added in each sample and further 500 µL of formic 
acid (5% w/v) was incorporated to mixture and 
vortexed for 5 min. Plasma samples were extracted 
with 2 mL of ethyl acetate for 5 minutes. Supernantant 
1.6ml was transferred to evaporation tubes and dried 
gently under nitrogen gas at 40 ˚C and reconstituted 
with 500 µL of mobile phase. An aliquot of 20 µL was 
injected onto an analytical column to perform the 
HPLC analysis.  
Study Design: The approval of the Institutional 
Animal Ethics Committee was obtained before starting 
the study. A total of nine healthy albino rabbits of 
either sex weighing 3.0-3.5kg were used for the study. 
The animals were kept in individual cages under well-
defined and standardized conditions (humidity and 
temperature controlled room) and fed with standard 
food and water access. Three groups consisting of 
three rabbits in each group was taken for the study. 
Paget and Barners table was used for the calculation of 
terbutaline sulphate dose in rabbits
27,28
. Accordingly, 
2.25 mg of terbutaline sulphate was fixed for rabbits 
taken for the study. The pure drug terbutaline sulphate 
and its optimized chronomodulated delivery system 
containing this dose were given to the animals. The 
rabbits were fasted overnight before the administration 
of the products. One group was kept as control and the 
other two groups were administered with terbutaline 
sulphate pure drug in suspension form and the 
optimized chronomodulated delivery system of 
terbutaline sulphate respectively. After collecting the 
zero hour blood sample (predose), the products were 
administered orally with 10 ml of water. The 
chronomodulated delivery system (capsule) was kept 
behind the tongue to avoid biting by rabbit. Blood 
samples (200μl) were withdrawn from the marginal ear 
vein at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 16 hrs for 
the pure drug and 2, 4, 6, 8, 10, 12, 14, 16, 18 and
 24hrs for the optimized chronomodulated 
delivery system. Blood samples were collected in 
heparinised tubes and were centrifuged at 3000rpm for 
10 minutes. Plasma was separated and collected into 
fresh tubes and stored at -20
°
C until further used for 
analysis. The serum concentration of terbutaline 
sulphate from both pure drug and its optimized 
chronomodulated delivery systems were measured by 
reverse phase HPLC method as stated earlier. Various 
pharmacokinetic parameters like Cmax, tmax, AUC, 
MRT and Kel were determined by using Kinetica 5.0 
software. 
DISCUSSION: 
Particle size and surface topography 
The average particle size of the microspheres was 
found to be in the range 4.63±0.48 to 11.75±0.92µm 
and is given in Table No 1. Particle size increased with 
increase in core: coat ratio which could be due to more 
amount of coat material in same volume of liquid 
droplet. The particle size decreased with increase in 
the reaction time which could be due to fact that, at 
greater extent of cross-linking, formation more densely 
cross-linked polymeric chains occurs leading to 
reduced particle size. The particle size also reduced 
with increase in the rpm which could be to higher 
turbulence or mechanical shear created within the 
dispersion medium leading to decreased particle size. 
The microspheres appeared to be roughly spherical 
with few pores on the external structure and the 
tendency of adhering to each other as revealed by the 
SEM images. The SEM images also showed the 
presence of some irregular particles which could be 
due mechanical stress during the stirring process or the 
movement of the moisture during the drying period. 
The SEM images of the optimized microspheres is 
given in Fig No 1. 
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Figure 1: SEM Photographs of optimized carboxymethyl chitosan microspheres of terbutaline sulphate (S1). 
A. 100X magnification and B. 400X magnification. 
 
Encapsulation efficiency 
The encapsulation efficiency of terbutaline loaded 
carboxymethyl chitosan microspheres was in the range 
of 78.13±2.86 to 89.2±3.53%. It was observed that, as 
the amount of coat material increased, more efficient 
entrapment of the drug within the polymeric matrix of 
the microspheres occurred thereby leading to higher 
encapsulation efficiency. The encapsulation efficiency 
also increased with extensive cross-linking conditions. 
This could be due to more denser cross-linking of 
polymeric chains that prevented the migration of drug 
into the dispersion medium resulting in higher 
encapsulation efficiency
29
. The results of the 
encapsulation efficiency is given in Table No:1. 
In vitro drug release studies 
Dissolution studies revealed that with increase in core: 
coat ratio the resulted in the reduced drug release. The 
retardation of drug release could be to the formation of 
thick gel at higher polymeric concentration that created 
a greater diffusion path length for the diffusion of the 
drug. It was observed that, as the cross-linking time of 
the microspheres increased there was a proportionate 
decrease in the drug release which could be due to 
reduction of the macromolecular chain mobility and the 
formation of more stable and rigid spheres. It is well 
known fact that, the particle size is controlled by the 
agitation speed and indeed particle size has marked 
effect on drug release. Hence in the present study, 
microspheres were prepared at various speeds (S1-S3) 
and were subjected for dissolution studies. It was 
observed that, as the rotation speed increased there was 
a proportionate increase in the drug release. This could 
be due to the fact that, at higher rotational speeds, the 
size of the microspheres was reduced leading to higher 
surface area which further resulted in higher drug 
release. The effect of core: coat ratio, reaction time and 
rotation speed on the drug release is given in Fig No 2, 
3 and 4 respectively. Microspheres of the batch S1 
which showed good encapsulation efficiency and also 
gave satisfactory drug release profile suitable for 
chronotherapeutic delivery of terbutaline sulphate and 
hence was selected for the further development of 
chronomodulated delivery systems. 
 
 
Figure 2: Effect of core: coat ratio on in vitro release of terbutaline sulphate from  carboxymethyl chitosan 
microspheres (C1-C4) 
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Figure 3: Effect of reaction time on in vitro release of terbutaline sulphate from carboxymethyl chitosan 
microspheres (R1-R3). 
 
 
Figure 4: Effect of rpm on in vitro release of terbutaline sulphate from carboxymethyl chitosan microspheres 
(S1-S3) 
 
Mechanism of drug release: 
The release profile of all the microspheres batches was 
best fitted in to the first order equation as observed 
from the highest correlation coefficient values (0.9659-
0.9959), indicating the first order drug release 
mechanism.  Plots of percent drug released versus 
square root of time were found to be linear with high 
correlation coefficient values (0.9039-0.9967) 
indicating that the drug release from the microspheres 
was diffusion controlled. Further, the release data was 
also analyzed by Korsmeyer-Peppas equation. The 
release exponent ‘n’ was in the range of 0.2748-0.5124 
indicating diffusion controlled Fickian drug release 
mechanism. 
Evaluation of chronomodulated delivery systems: 
Formaldehyde treated capsule bodies: 
In about 100 capsule bodies treated with formaldehyde, 
about 8-10 bodies were found to be shrunk or distorted. 
The capsule bodies which were shrunk or distorted 
after the formaldehyde treatment were discarded for the 
further studies. The formaldehyde capsules were also 
tested for the presence of free formaldehyde. The 
sample solution was not more intensely colored than 
the standard solution inferring that less than 20μg/ml of 
free formaldehyde per 25 capsules, taken for test. 
In vitro dissolution studies: 
From the results of the in vitro release studies, it is 
clear that, all the capsules remained intact in the acidic 
pH for the initial 2 hrs of the dissolution studies, 
indicating the integrity of the enteric coating with 
HPMCP. Further, when the dissolution medium was 
changed to pH 7.4, the enteric coating along with the 
soluble cap dissolved thereby exposing the hydrogel 
plug to the dissolution medium. The exposed hydrogel 
plug then, absorbed the surrounding fluid, swelled and 
ejected thereby releasing the drug loaded microspheres 
into the dissolution media. With all the formulations, 
there was absolutely no drug release in pH 1.2, thus 
indicating the efficacy of enteric coating with HPMCP. 
In order to assess the release of terbutaline sulphate 
from the chronomodulated delivery systems, various 
semisynthetic polymers like sodium alginate, HPMC 
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and HPC in the concentrations of 60, 50, 40 and 30% 
w/w were used in the preparation of tablet plugs. 
Chronomodulated delivery systems of batches TSA1-
TSA4 were prepared with sodium as plugging material.  
The cumulative drug release at the end of 5th was 
found to be 6.38% for TSA1, whereas TSA2 and TSA3 
released 4.63 and 8.97% at the end of 4
th
 hr 
respectively. Formulation TSA4 with the lowest 
sodium alginate concentration (30%) released 7.89% of 
terbutaline at the end of 3
rd
 hr of dissolution study. 
After the complete ejection of the tablet plug, the 
release of terbutaline sulphate was found to be 93.63, 
95.07, 97.12 and 99.31% for TSA1, TSA2, TSA3 and 
TSA4 respectively. The results of the drug release 
studies from the chronomodulated delivery systems 
prepared using sodium alginate as hydrogel tablet plug 
is given in Fig No 5. 
HPMC K4M in the concentration of 60, 50, 40 and 
30% w/w was used as tablet plugging material in the 
chronomodulated delivery systems of THM1, THM2, 
THM3 and THM4 batches respectively. The 
cumulative drug release for THM1, THM2, THM3 and 
THM4 were found to be 2.98 and 3.69, 2.71 and 4.25% 
at the end of 7, 6, 5 and 4hrs respectively. The 
cumulative amount of drug release after the complete 
ejection of the tablet plug was found to be 88.35, 
92.16, 94.88 and 98.39 % for THM1, THM2, THM3 
and THM4 respectively at the end of 16hrs dissolution 
study. The results of the drug release studies from the 
chronomodulated delivery systems prepared using 
HPMC K4M as hydrogel tablet plug is given in Fig No 
6. 
In another set of formulations, hydroxypropyl cellulose 
(HPC) as a hydrogel plugging material in four different 
concentrations like 60, 50, 40 and 30 mg were used in 
chronomodulated delivery systems of THC1, THC2, 
THC3 and THC4 respectively. The results of the drug 
release studies from the chronomodulated delivery 
systems prepared using HPC as hydrogel tablet plug is 
given in Fig No 7. The cumulative drug release from 
THC1 and THC2 was found to be 3.87 and 5.33% at 
the end of 8
th
 and 7
th
 hrs respectively, whereas 4.73 and 
8.69% drug was released at the end of 6
th
 hr for THC3 
and THC4 respectively. The cumulative amount of 
drug release after the complete ejection of the tablet 
plug was found to be 83.35, 88.54, 92.87 and 95.28% 
for THC1, THC2, THC3 and THC4 respectively at the 
end of 16hrs dissolution study. From all the 
formulations, it was observed that, as the polymer 
concentration in the hydrogel plug was increased, there 
was a proportionate delay in the ejection of the 
hydrogel plug. This could be attributed to delayed 
wetting and swelling of the hydrogel material at the 
higher polymeric concentration that resulted in higher 
lag time. However, the lag time observed in case of 
formulations of HPC was higher when compared to 
that of sodium alginate and HPMC. This could be 
probably due to slower hydration and swelling of the 
HPC leading to delayed ejection of the plug. The rank 
order of drug release sustaining ability of different 
semisynthetic polymers used in the preparation of 
tablet plug was in the following order: 
HPC>HPMC>sodium alginate. 
 
 
Figure 5: In vitro release of terbutaline sulphate from chronomodulated delivery systems  with sodium 
alginate as tablet plug 
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Figure 6: In vitro release of terbutaline sulphate from chronomodulateddelivery  systems with HPMC as tablet plug 
 
 
Figure 7: In vitro release of terbutaline sulphate from chronomodulateddelivery  systems with HPC as tablet plug 
 
Mechanism of drug release: 
The ‘r’ values for zero order and first order kinetics 
were found in the range of 0.7974-0.9268 and 0.9787-
0.9975 respectively. Higher correlation coefficient 
values were found for first order compared to zero 
order kinetics, indicating first order release mechanism. 
When the data was fitted to Higuchi’s model, high 
correlation coefficient values ranging from 0.8742-
0.9496 were observed indicating the diffusion 
controlled release mechanism. Further, to analyze the 
nature of the diffusion controlled release mechanism, 
the release data was also fitted into Korsmeyer and 
Peppas equation. The ‘r’ values for Korsmeyer and 
Peppas were in the range of 0.9346-0.9840 and the ‘n’ 
values were found between 0.4591-0.9185 indicating 
non-Fickian diffusion controlled drug release. Overall, 
the kinetic analysis of the drug release data from 
various chronomodulated delivery systems of 
terbutaline sulphate revealed first order diffusion 
controlled non-Fickian release mechanism. 
Roentgenographic studies: 
Roentgenographic studies were carried out on healthy 
male albino rabbits to assess the in vivo behaviour of 
the optimized chronomodulated delivery systems of 
terbutaline sulphate (THM4). At different time 
intervals (0, 2, 4, 6 and 8hrs), X-ray images were taken 
to follow the movement, location and the integrity of 
the chronomodulated systems in different parts of 
gastro intestinal tract. X-ray photographs taken after 
2hrs, indicated the presence of chronomodulated 
delivery system in the stomach which further moved to 
the small intestinal region as observed from the 
photograph taken after 4hrs of the study. The 
chronomodulated system remained intact both in the 
stomach and small intestine of the rabbit as revealed 
from the x-ray photographs. The photographs taken at 
the end of 6
th
 hr revealed the release of barium sulphate 
loaded microspheres in to the small intestine due to the 
ejection of the tablet plug. The microspheres remained 
adhered to the small intestinal region due to the 
mucoadhesive nature of the chitosan used in the 
preparation of microspheres as observed from the x-ray 
photograph taken at the end of 8
th
 hr study. The results 
of the in vivo Roentgenographic study were in 
accordance with the in vitro dissolution studies in 
which the chronomodulated delivery system remained 
intact for first 4hrs after which the ejection of the tablet 
plug occurred with the liberation of microspheres. 
Overall, the Roentgenographic studies revealed the 
predicted in vivo performance of the developed 
chronomodulated delivery systems of terbutaline 
sulphate. The results of the in vivo Roentgenographic 
studies for the optimized chronomodulated delivery 
systems of terbutaline sulphate (THM4) is given Fig 
No 8. 
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I. X-Ray image taken at 0 hrs 
 
II. X-Ray image taken after 2 hrs 
 
 
III. X-Ray image taken after 4 hrs 
 
IV. X-Ray image taken after 6 hrs 
 
 
V. X-Ray image taken after 8 hrs 
Figure 8: In vivo Roentgenographic evaluation of optimized chronomodulated delivery systems of terbutaline 
sulphate (THM4) in rabbits. 
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In vivo Pharmacokinetic studies 
The plasma concentration versus time profile of pure 
drug terbutaline sulphate and its optimized 
chronomodulated drug delivery system is given in Fig 
No 9. The data obtained from the in vivo HPLC 
analysis of rabbit plasma samples of both terbutaline 
sulphate pure drug and its optimized chronomodulated 
delivery system (THM4) was used to determine various 
pharmacokinetic parameters using Kinetica 5.0 
software. 
 
 
Figure 9: Mean serum concentrations versus time curve 
of terbutaline sulphate pure drug and its optimized 
chronomodulated delivery system (THM4) 
 
 The pure drug terbutaline sulphate showed the mean 
Cmax of 208.74±9.82ng/ml, tmax of 2hrs, AUCtotal of 
1074.78±31.1 ng/ml/hr, t1/2 of 2.27±0.95 hrs, MRT of 
5.689±0.37 hrs and Kel of 0.3052±09 hr
-1
. The 
optimized chronomodulated system of terbutaline 
sulphate (THM4) exhibited the mean Cmax of 153.11 
±9.44 ng/ml, tmax of 10 hrs, AUCtotal of 1461.133±105.0 
ng/ml/hr, t1/2 of 4.01±0.156 hrs, MRT of 
12.614±0.249hrs and Kel of 0.1728±0.007 hr
-1
. 
Pharmacokinetic analysis clearly revealed the 
significant increase in tmax, AUC and MRT of 
optimized chronomodulated system of terbutaline 
sulphate compared to that of pure drug. The study 
demonstrated the time delayed drug release and 
improved pharmacokinetic parameters of the 
terbutaline sulphate from its optimized 
chronomodulated delivery systems.  
CONCLUSIONS: 
The glutaraldehyde cross-linked carboxymethyl 
chitosan microspheres appeared to be roughly spherical 
with the size range of 4.63±0.48 to 11.75±0.92µm. 
Particle size, encapsulation efficiency and release rate 
are dependent on the fabrication conditions of the 
microspheres. Drug release from the microspheres 
depended on core: coat ratio, reaction time and the 
rotational speed used in the preparation of 
microspheres.  Formaldehyde treatment efficiently 
rendered the hard gelatine capsule bodies water 
insoluble. The ejection of the plug from the 
chrnomodulated delivery system depended on the 
nature and concentration of polymer used in the 
preparation of table plug. Among the different 
polymers studied HPC showed highest lag time 
compared to HPMC K4 M and sodium alginate. The 
Roentgenographic studies revealed the predicted in 
vivo performance of the developed chronomodulated 
delivery systems of terbutaline sulphate. 
Pharmacokinetic analysis revealed the significant 
increase in tmax, AUC and MRT of optimized 
chronomodulated system of terbutaline sulphate 
compared to that of pure drug. The results of the study 
conclusively proved the suitability of carboxymethyl 
chitosan microspheres and the adopted Pulsincap 
technology in the development of chronomodulated 
delivery systems for terbutaline sulphate in the 
treatment of nocturnal asthma. 
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